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Abstract
Background: G-CSF is a critical regulator of
hematopoietic cell proliferation, differentiation and
survival. It has been reported that G-CSF attenuates
renal injury during acute ischemia-reperfusion. In this
study we evaluated the effects of G-CSF on the renal
and cardiovascular systems of 2K1C hypertensive
mice. Methods: Male C57BL/6 mice were subjected
to left renal artery clipping (2K1C) or sham operation
and were then administered G-CSF (100 µg/kg/day)
or vehicle for 14 days. Results: Arterial pressure was
higher in 2K1C + vehicle animals than in 2K1C + G-
CSF (150±5 vs. 129±2 mmHg, p<0.01, n=8). Plasma
angiotensin I, II and 1-7 concentrations were
significantly increased in 2K1C + Vehicle when
compared to the normotensive Sham group. G-CSF
prevented the increase of these vasoactive peptides.
The clipped kidney/contralateral kidney weight ratio
showed a less atrophy of the ischemic kidney in the
treated group (0.50±0.02 vs. 0.66±0.01, p<0.05). The
infarction area in the clipped kidney was completely
prevented in 7 out of 8 2K1C + G-CSF mice.
Administration of G-CSF protected the clipped kidney
from apoptosis. Conclusion: Our data indicate that
G-CSF prevents kidney infarction and markedly
attenuates the increases in plasma angiotensin levels
and hypertension in 2K1C mice, reinforcing the
protective effect of G-CSF on kidney ischemia.
Introduction
Granulocyte colony-stimulating factor (G-CSF)
promotes the proliferation and differentiation of myeloid
progenitor cells including the mobilization of bone marrow
stem cells [1-4]. G-CSF exerts reparative and
regenerative effects in various ischemic tissues, including
heart [3, 5], brain [6] and kidney [7]. Additionally,
pretreatment with G-CSF attenuates renal ischemia/
reperfusion injury, and this cytoprotection seems to be
associated with its anti-apoptotic action [8].
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Even though the kidney has a remarkable capacity
to regenerate after injury, progressive and irreversible
insults result in chronic renal disease [9]. However, little
is known about the potential of G-CSF in protection against
permanent kidney injury. The experimental murine model
of renovascular hypertension, which is induced by partial
clipping of the left kidney artery [10], seems suitable to
test the protective actions of G-CSF in a form of persistent
renal ischemia/infarction not yet studied. Moreover, in
this model of hypertension, the reduced perfusion pressure
in the artery of the clipped kidney stimulates the renin-
angiotensin system.
Therefore, in the present study we tested the
hypothesis that G-CSF has a cytoprotective effect on
renal ischemia/infarction and that this could help prevent
or attenuate the development of renovascular
hypertension in the mouse.
Materials and Methods
Animals
The experiments were performed with 8- to 9-week-old
male C57BL/6 mice (n=62), averaging 23 g, obtained from the
breeding facilities of the Health Sciences Center at the Federal
University of Espirito Santo. The animals were housed
according to the institutional guidelines for animal research,
including constant room temperature, 12-hour light/dark cycle,
50±5% humidity, standard mouse chow and water ad libitum.
The procedures were previously approved by the Animal Use
Ethics Committee of the Research Center of Emescam College
of Health Sciences (Protocol # 006/2009).
Two-kidney, one-clip (2K1C) hypertension was produced
using stainless steel clips (0.12 mm opening width, Exidel SA,
Switzerland). The clip was placed around the left renal artery
according to the procedure described by others [10-12]. Age-
matched Sham mice were used as control animals. Immediately
after surgery, groups of 2K1C and Sham mice were administered
recombinant human G-CSF (Filgrastim®, Bio Sidus S.A.,
Argentina; 100 µg/kg/day, s.c.) for 14 days. An equal number
of animals per group received vehicle (5% glucose solution).
Surgical Procedures for Hemodynamic Measurements
Mice were anesthetized with ketamine/xylazine (91.0/9.1
mg/kg, i.p.), and catheters (0.040 mm O.D. x 0.025 I.D., Micro-
Renathane, Braintree Science Inc., MA, USA) were inserted
into the right carotid artery for direct measurement of mean,
systolic and diastolic arterial pressure and heart rate.
Experiments were performed in conscious, freely moving mice
48 hours after catheter placement. For mean arterial pressure
and heart rate recordings, the arterial catheter was plugged
into a disposable blood pressure transducer (Cobe Laboratories
Inc., Lakewood, CO, USA) and connected to a pressure
processor amplifier and data acquisition system (MP100,
Biopac Systems Inc., Goleta, CA, USA).
Biochemical Analyses
Mice were placed in metabolic cages for a 24-hour
adaptation period followed by another 24-hour period for
biochemical analysis of urine. After that, animals were
euthanized, and their blood was collected for creatinine and
urea measurements. Plasma and urinary creatinine were
measured by Jaffe’s method using a creatinine test kit (Bioclin®,
Belo Horizonte, Brazil). Proteinuria was measured in urine
samples by spectrophotometry (SP-220, Bioespectro, Sao Paulo,
Brazil) after endpoint reaction with a colorimetric kit (Sensiprot,
Labtest Diagnostica S.A., Sao Paulo, Brazil).
Blood and Tissue Samples
Animals were euthanized in a CO2 chamber. Immediately
after, blood samples were collected from the right ventricle to
determine hematological features using a T890 Hematology
Analyzer (Beckman Coulter Inc., Fullerton, CA, USA).
Mononuclear cells (MNCs) were isolated from both femur and
tibia bone marrow and from the spleen using a gradient
(Histopaque® - 1083, Sigma-Aldrich, Saint Louis, MO, USA)
and then counted in a Neubauer chamber. Ventricles, kidneys
and spleen were excised and dried for 48 h in an oven at 37°C
for weight determination. Ventricular weight index was calculated
as dry weight/body weight (mg/g). The left kidney weight/
right kidney weight ratio was also calculated.
Measurements of Plasma Angiotensin Levels
Blood was collected in the presence of EDTA and
protease inhibitor cocktail (Product # P2714, Sigma-Aldrich),
and samples were centrifuged at 9.5 g for 15 min in a refrigerated
centrifuge (4°C) to remove the plasma for later analysis.
Angiotensins were extracted in Oasis C18 columns previously
activated with methanol (5 mL), tetrahydrofuran (5 mL), hexane
(5 mL), methanol (5 mL) and water (10 mL). After activation, the
samples were applied to the columns, washed with water and
eluted in ethanol/acetic acid/water in the proportions 90% - 4%
- 6%. The eluates were dried, redissolved in 500 µL of mobile
phase A (5% acetonitrile in 0.1% phosphoric acid) and filtered
for analysis by high performance liquid chromatography
(HPLC). The angiotensin in each sample was separated in a
reversed-phase ODS Aquapore300 (250 x 4.6 mm) HPLC column,
7µm particle size (PerkinElmer’s Brownlee Columns, Norwalk,
USA), using the gradient 5–35% of mobile phase B: 95%
acetonitrile in 0.1% phosphoric acid under a flow of 1.5 mL/min
for 40 min. The angiotensins were identified by comparing them
with the retention times of standard angiotensins.
Histological Kidney Processing and Morphometry
Kidneys were removed and fixed in 4% buffered
formaldehyde solution for 48 hours, embedded in paraffin, and
sectioned at 5 µm thicknesses, and slides were stained with
hematoxylin-eosin (Sigma-Aldrich). Evident color differences
in the captured images of kidney infarct areas stained with
hematoxylin-eosin were quantified using Image J software
(1.33u, Public Domain; National Institutes of Health, Bethesda,
USA). Picrosirius red for collagen I-specific staining was
performed to evaluate the effect of G-CSF on kidney
glomerulosclerosis. A total of 20 glomeruli were randomly used
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to calculate the percentage of stained area of each kidney at
400x magnification. Images of individual glomerular areas were
captured with a color video camera (VKC150, Hitachi, Tokyo,
Japan) connected to a microscope (AX70, Olympus, Center
Valley, PA, USA) and quantified using Image J. In all histological
and morphometric analyses, the examiner was blinded to the
experimental groups.
TUNEL Assay
A separate group of 2K1C mice (n=10) was sacrificed 48
hours after renal artery clipping for evaluation of cell death by
measuring DNA fragmentation using an in situ terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) Cell Death Detection Kit, POD (Product # 11 684 817
910, Roche, Mannheim, Germany). TUNEL assay was performed
on paraffin-embedded sections from cortex of ischemic kidney.
Typical images were captured with a color video camera (Nikon
Digital Sight DS - U2) connected to a fluorescence microscope
(Nikon Instruments Inc., Melville, NY, USA) by using excitation
wavelengths in the range of 450–500 nm and detection in the
range of 515–565 nm (green). DNAse-treated (Macherey-Nagel,
Düren, Germany) sections were used as positive controls,
according to the protocols of the manufacturer. TUNEL-
positive tubular cells in proximal and distal tubules were
counted from 5 different cortical fields and averaged in each
section (4/animal), by using a high-power-field (hpf, x200). All
tissue sections were viewed and labeled a blinded examiner.
Statistical Analyses
All data are expressed as means±SEM. The means of
groups and the interaction of factors were compared by two-
way ANOVA followed by the post hoc Fisher test or Student´s
t-test for independent samples when appropriate. The level of
significance was set at p<0.05.
Results
Body weight, cardiac weight index, and
hemodynamic parameters
Initial body weight was statistically similar among
groups. At the end of experiments, body weight was
reduced (p<0.05, two-way ANOVA) in hypertensive
groups (Vehicle: 23.1±0.4 g and G-CSF: 22.8±0.2 g) when
compared to their respective Sham groups (Vehicle: 24.2
± 0.4 g and G-CSF: 23.5±0.3 g). As shown in Fig. 1
(bottom panel), cardiac weight index was significantly
higher in the 2K1C than in the Sham (1.31±0.06 vs.
1.05±0.02 mg/g, p<0.01, two-way ANOVA) group,
without significant effects of G-CSF in between the 2K1C
and Sham groups (1.22±0.03 vs. 1.31±0.06 mg/g).
Figure 1 shows the effect of G-CSF administered
for 14 days on hemodynamic parameters in hypertensive
animals. As expected, 14 days after renal artery clipping,
2K1C mice showed arterial hypertension (systolic,
diastolic and mean arterial pressure: 182±7, 119±2, 150±5
mmHg, respectively) when compared to the Sham group
(128±2, 82±1, 105±1 mmHg, respectively; p<0.01, two-
way ANOVA). G-CSF did not modify arterial blood
pressure in normotensive animals but caused a significant
attenuation of hypertension (about -23 mmHg) in 2K1C
animals (p<0.01, for interaction). As expected,
hypertension in 2K1C animals was accompanied by
tachycardia, which was not significantly affected by the
G-CSF.
Hematological features
The effects of G-CSF on hematological features,
mononuclear cells (MNCs) number and spleen weight in
Sham and 2K1C animals are summarized in Table 1. 2K1C
hypertensive animals showed a significant increases in
the numbers of leukocytes and the subpopulation of
Fig. 1. Bar graphs showing the effects of G-CSF administration
for 14 days on hemodynamic parameters in normotensive (Sham,
n=8) and hypertensive (2K1C, n=8) mice. MAP: mean arterial
pressure, HR: heart rate, VW/BW: ventricular weight/body
weight . *p< 0.01 vs. 2K1C vehicle group; ##p < 0.01 vs. respective
Sham group. Values are mean ± SEM.
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neutrophils when compared to Sham normotensive animals
(p<0.05, two-way ANOVA). G-CSF caused a significant
increase in the number of white blood cells in both
normotensive (p<0.01, two-way ANOVA) and
hypertensive (p<0.05) animals when compared to their
respective vehicle-treated groups. The number of
neutrophils was significantly augmented by both
hypertension (about 4-fold) and G-CSF administration
(about 9-fold) when compared to Sham normotensive
animals. The number of lymphocytes was significantly
increased (about 2.5-fold) only in normotensive animals
treated with G-CSF. The numbers of other white blood
cells, such as monocytes, eosinophils and basophils, were
influenced neither by hypertension nor by G-CSF
administration (data not shown). Neither hypertension nor
G-CSF administration caused a significant change in
erythrocytes number, platelet number, hemoglobin, or
hematocrit. MNCs were elevated in tibia and femur bone
marrow from normotensive animals treated with G-CSF
(about 2-fold). MNCs from the spleen were significantly
augmented by G-CSF administration (about 3-fold) and
additively by hypertension (about 5.5-fold). G-CSF
administration caused a significant increase in the spleen
dry weight in both normotensive (p<0.01, two-way
ANOVA) and hypertensive (p<0.05) animals.
Plasma angiotensin
Figure 2 shows average values of plasma
angiotensin. As expected, 2K1C hypertensive animals
Fig. 2. Bar graphs showing the effects of G-CSF administration
for 14 days on plasma angiotensin I (Ang I), II (Ang II) and 1-
7 (Ang 1-7) in normotensive (Sham, n=8) and hypertensive
(2K1C, n=13) mice. Values are mean ± SEM. **p< 0.01 vs. 2K1C
vehicle group; ##p < 0.01 vs. the respective Sham groups (two-
way ANOVA).
Table 1. Effects of G-CSF administration on hematological features, MNCs number
and spleen weight in normotensive (Sham) and hypertensive (2K1C) mice. Values are
mean ± SEM from the number of animals indicated in parentheses. BM, bone marrow;
MNCs, mononuclear cells; *p< 0.05 and **p< 0.01 vs. respective Vehicle group;
#p<0.05 vs. respective Sham group (two-way ANOVA).
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Fig. 3. Left panel: typical
photomacrography of the clipped
(white arrows) and the
contralateral kidney showing the
attenuation of atrophy by G-CSF
administration in a 2K1C
hypertensive mouse compared
with a mouse receiving vehicle.
Right panel: bar graph showing
left kidney/right kidney weight
ratio (LKW/RKW) in normo-
tensive Sham, n=8) and
hypertensive (2K1C, n=8) mice
treated with G-CSF. *p<0.05 vs.
2K1C Vehicle group; ##p<0.01 vs.
the respective Sham group (two-
way ANOVA).
Fig. 4. Left top panel shows
typical histological micrographs
from clipped kidneys stained with
hematoxylin-eosin. A: image from
a 2K1C+Vehicle mouse showing
a large infarcted area containing
no nuclei (pink staining;
coagulative necrosis). a: higher
magnification showing a renal
corpuscle with a “ghost
glomerulus’’ containing
erythrocytes. B and b are images
of a 2K1C mouse treated with G-
CSF, showing its protective effect
against the advent of renal
infarction. Right bar graph shows
the effect of G-CSF administration
on kidney infarct area in 2K1C
mice (n=8) compared with the
2K1C+Vehicle group (n=8);
*p<0.05 vs. Vehicle group
(Student’s t test). Bottom panel:
representative images from
TUNEL assay showing that the
process of apoptosis (green fluorescent tubular cells, indicated by arrows) in an ischemic kidney from a 2K1C+Vehicle mouse (C)
was prevented in a 2K1C mouse treated with G-CSF for 48 hours (D). Bottom bar graph shows a significant difference in the
number of TUNEL-positive tubular cells between 2K1C+ Vehicle (n=5) and 2K1C + G-CSF groups (n=5); *p<0.01 vs. Vehicle group
(Student’s t test), suggesting a protective effect of G-CSF on renal tubular apoptosis.
showed significant increases (p<0.01, two-way ANOVA)
in angiotensin I (164±11 pmol/mL), angiotensin II (142±11
pmol/mL) and angiotensin 1-7 (177±12 pmol/mL) when
compared to Sham animals (85±6, 30±5 and 88±7 pmol/
mL, respectively). G-CSF administration did not affect
angiotensin levels in Sham animals. In contrast, this G-
CSF did prevent the increase of plasma angiotensin I
(p<0.01, two-way ANOVA) and significantly attenuated
the increase of plasma angiotensin II (p<0.01) in 2K1C
hypertensive mice. The increase in plasma angiotensin
1-7 also was prevented by G-CSF administration (p<0.01,
two-way ANOVA) in these hypertensive animals. The
Effects of G-CSF on 2K1C Hypertension Cell Physiol Biochem 2012;29:143-152
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two-way ANOVA showed a significant interaction
(p<0.05) between factors (drug treatment and
hypertension model) in all tested variables.
Morphological analysis of the kidneys
The effects of G-CSF administration on kidney
morphology in normotensive and hypertensive mice are
shown in Fig. 3. The left panel contains typical
photomacrographs showing atrophy and a coagulative
necrosis area in the clipped kidney and hypertrophy of
the nonclipped kidney in a hypertensive mouse compared
to the kidneys of a normotensive Sham mouse. As
illustrated, G-CSF administration had a preventive effect
on these developments in the clipped kidney of the
hypertensive mouse. As summarized in the bar graph, G-
CSF administration did not affect the left kidney weight/
right kidney weight ratio in normotensive Sham animals
(p>0.05, two-way ANOVA). In contrast, it was observed
the characteristic decrease in this ratio in hypertensive
2K1C animals when compared to Sham groups (p<0.01,
two-way ANOVA) and that it was significantly attenuated
(p<0.05, two-way ANOVA) by G-CSF administration.
Figure 4 shows the effects of G-CSF administration
on the infarction of the clipped kidney of 2K1C
hypertensive animals. Panel A shows a typical infarcted
tissue in a section of clipped kidney from a 2K1C+Vehicle
mouse (Fig. 4, panel A), which was characterized by light
staining (hematoxylin-eosin) with no nuclei and very little
structural damage, giving the appearance of  “ghost cells’’
(Fig. 4, panel a). In contrast, the sections from a 2K1C
mouse treated with G-CSF for 14 days (panels B and b)
Fig. 5. Right panel shows
typical histological
micrographs from clipped
kidneys stained with
Picrosirius red. Left bar
graph shows the effect of G-
CSF administration on
kidney glomerular collagen
in 2K1C mice (n=7)
compared with the
2K1C+Vehicle group (n=5).
**p<0.01 vs. Vehicle group
(Student’s t test).
do not show such characteristics. The average kidney
infarcted area in the bar graph (Fig. 4, right panel) shows
that G-CSF administration prevented (p<0.05, Student’s
t test) kidney infarction of the ischemic kidney in 2K1C
animals compared to 2K1C non-treated animals: G-CSF
administration prevented clipped kidney infarction in 7
out of 8 2K1C animals. In addition, Fig. 4 shows typical
sections from cortex of an ischemic kidney, in which it
can be observed TUNEL-positive tubular cells. As shown
in those sections, the protective effect of G-CSF
administration on apoptosis was already evident at 48
hours after kidney clipping, as indicated by the large
number of green fluorescent cells in the clipped kidney
of a 2K1C non-treated mouse compared to the small
number in the 2K1C treated mouse (Fig. 4, panels C and
D). On average, the number of TUNEL-positive tubular
cells was significantly decreased (p<0.01, Student’s t test)
in 2K1C mice administered with G-CSF when compared
with the Vehicle group (12±3 vs. 46±7 cells/hpf) (Fig. 4,
bottom bar graph).
Typical photomicrographs of the accumulation of
collagen I in kidney glomeruli of a 2K1C hypertensive
mouse in contrast with a reduced collagen I content in a
2K1C mouse administered with G-CSF are shown in Fig.
5. On average, glomerular collagen I in 2K1C
hypertensive mice was significantly increase when
compared with Sham mice (69±4 vs. 35±1%, p<0.01,
Student’s t test). In 2K1C animals administered with G-
CSF, glomerular deposition of collagen I was similar
(44±5%, p>0.05, Student’s t test) to that observed in Sham
mice (Fig. 5, bar graph).
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Renal function
Table 2 summarizes the values of parameters of
renal function. 2K1C animals showed an increased 24-
hour urine volume compared to Sham animals (p<0.05,
two-way ANOVA), which was not modified by G-CSF
administration. However, neither renovascular
hypertension nor G-CSF had a significant effect on urine
or plasma creatinine, plasma urea and proteinuria,
indicating similar renal function between groups.
Discussion
The main findings of this study were a marked
protective effect of G-CSF against kidney infarction and
hypertension development in the murine model of
angiotensin II-dependent renovascular hypertension.
Jia et al. [13] reported that administration of G-CSF
in mice infused with angiotensin II by using an osmotic
minipump reduced cardiac hypertrophy but did not affect
blood pressure. In contrast, in our study we used a classical
model of renovascular hypertension in which angiotensin
II is endogenously increased due to the stenosis of the
kidney artery. As previously observed by others [10, 14,
15], the 2K1C procedure in the mouse resulted in the
development of hypertension accompanied by activation
of the renin-angiotensin system. We observed that G-
CSF administration significantly attenuated the
development of hypertension by about 23 mmHg.
Ventricular hypertrophy and tachycardia have been
previously reported in this model of hypertension 4 weeks
after renal artery clipping [10, 12] and we obtained similar
findings at two weeks after the procedure. G-CSF
administration did not have a significant preventive effect
on the development of these two parameters. In a model
of exogenous angiotensin-dependent hypertension, others
have reported a partial attenuation of ventricular
hypertrophy by G-CSF administration for 4 weeks even
without effects on hypertension [13].
We chose to use the 2K1C hypertensive mice
because the goal of the present study was to investigate
the protective effect of G-CSF on a model of persistent
kidney ischemia. G-CSF ameliorates toxic renal injury
caused by cisplatin [16] and ischemic renal injury [17] in
animal models of ischemia/reperfusion [7]. In the present
study we observed that G-CSF reduced the atrophy of
the clipped kidney in hypertensive mice, as evidenced by
the clipped kidney/contralateral kidney weight ratio, and
prevented kidney infarction. Based on the study of
Stokman et al. [17] the underlying mechanism by which
G-CSF protects the kidney against ischemia is probably
not due to stem cell transdifferentiation but to altered
inflammatory kinetics. Recently Li et al. [8] demonstrated
that the anti-apoptotic effect of G-CSF on ischemic kidney
of C57 mice is via PI3K/Akt activation. This idea is
corroborated by our observation of a protective effect of
G-CSF against apoptosis in the ischemic kidney of 2K1C
hypertensive mice, as indicated by increased DNA
fragmentation in the TUNEL assay.
A notable consequence of prevention of kidney
ischemia promoted by G-CSF was the marked reductions
in plasma angiotensin I and II in hypertensive mice. The
decrease in plasma angiotensin II in these animals seems
to be the reason 2K1C animals treated with G-CSF
showed a significant attenuation of hypertension. Recently,
Jia et al. [13] showed that mice administered with
angiotensin II or angiotensin II plus G-CSF have similar
levels of arterial hypertension. This finding favors our
hypothesis that the reduced angiotensin II we observed
in 2K1C mice administered with G-CSF may be a
Table 2. Markers of renal function in normotensive and 2K1C hypertensive mice treated with
G-CSF. Values are mean ± SEM from the number of animals indicated in parentheses. #p< 0.05 vs.
Sham group.
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consequence of a protective effect of this cytokine on
the kidney. This is evidenced by the observation that the
action of G-CSF was restricted to hypertensive mice and
supported by the significant interaction between factors
(two-way ANOVA). Considering that G-CSF facilitates
vascular regeneration in a mouse model of ischemia/
reperfusion [18], we speculate that the improvement of
renal blood perfusion in the clipped kidney in our study, in
addition to a direct effect of G-CSF in juxtaglomerular
cells, resulted in reduced liberation of renin. Although
angiotensin 1-7 acts in an important endogenous
counterbalancing mechanism that attenuates the
hypertensive actions of angiotensin II [19], the decreased
plasma level of this peptide in G-CSF 2K1C mice was
expected because it follows the plasma concentration of
angiotensin I and II [20].
Glomerulosclerosis has been reported in 2K1C
hypertensive rats [21]. In the present study we observed
a high glomerular collagen I content in a murine model of
renovascular hypertension. G-CSF administration
prevented collagen I deposition in the clipped kidney of
hypertensive mice. This beneficial effect of G-CSF seems
to be more related to angiotensin II-induced renal
pathologies. However, Stokman et al. [22] reported that
G-CSF did not ameliorate the renal fibrosis in a mouse
model of chronic obstructive nephropathy. Others have
observed in C57 mice with angiotensin II-induced cardiac
remodeling a cardioprotective effect of G-CSF, which
was characterized by reduced fibrosis through inhibition
of osteopontin and modulation of the expression of
angiotensin-converting enzyme isoforms [13]. Moreover,
others have reported that tumor necrosis factor–induced
angiotensin II AT1 receptor upregulation enhances cardiac
fibrosis process [23] and that tumor necrosis factor-α,
AT1 receptor and transforming growth factor-β1 are
reduced by G-CSF in a chronic heart failure model [24].
Further studies are necessary to elucidate if the above
mechanisms of cardioprotection by G-CSF could also be
involved in the renoprotective effect of this cytokine in
2K1C hypertensive mice. A limitation in the morphological
analysis is the lack of an accurate randomization to include
specific kidney regions into the analysis. This was not
done because the infarcted area had a diffuse occurrence
and covered most of the kidney, i.e., most of the glomeruli
were located in infarct zones of collagen deposition.
Importantly, likewise in a study in the murine model of
2K1C hypertension by others [25], our results are based
on a morphometric analysis done in a blinded fashion.
Despite a reduced blood flow to the clipped kidney
with a consequent reduction in its glomerular filtrations
rate, the 2K1C model of hypertension does not increase
total body fluid volume because pressure diuresis in the
unclipped kidney prevents hypervolemia. In our analysis
of kidney function, we observed increased urinary volume
in both 2K1C + Vehicle and 2K1C + G-CSF mice, in
agreement with findings in 2K1C hypertensive rats
showing increased urinary volume without significant
changes in fractional sodium excretion [26]. This polyuria
is correlated with the polydipsia reported by Santos et al.
[27] in the same murine model and could be due to the
dipsogenic actions of angiotensin on the brain [28].
Although the clipped kidney showed morphological
damage, plasma urea level, plasma and urine creatinine
levels and proteinuria, which are predictors of renal
function, were similar to those observed in Sham mice.
This finding is not surprising because the contralateral
kidney is hypertrophic and compensates for the
dysfunction of the clipped kidney. G-CSF administration
did affect renal function in Sham normotensive or 2K1C
hypertensive mice. This finding is in agreement with many
others [see review 7]. However, Tögel et al. [29] observed
that G-CSF administration increased plasma creatinine,
associated with granulocytosis, in a murine model of acute
renal failure, and therefore, the therapeutic use of G-CSF
should be approached with caution in this disease.
Neutrophils are among the first cells to be recruited
to defend the body against invading pathogens and injury,
but they are a major cause of pathology when uncontrolled
[30]. Bone marrow, liver and spleen are each responsible
for the clearance of approximately 30% of neutrophils
from the circulation under homeostatic conditions [31].
We observed an increase in circulating neutrophils in 2K1C
hypertensive mice compared with Sham normotensive
mice. Administration of G-CSF, which is widely used in
the treatment of neutropenic conditions [32], increased
both the number of neutrophils and spleen weight in the
Sham group, confirming the effectiveness of this drug. In
2K1C hypertensive mice administration of G-CSF
increased spleen weight and had an additive effect on
neutrophilia. The stimulatory effect of G-CSF on the
spleen is in agreement with other findings that this drug
promotes an enlargement of spleen in humans [33].
As expected, we observed a stimulatory effect of
G-CSF on mononuclear cells in the spleen and bone
marrow in Sham normotensive mice, in agreement with
others [2, 34]. In 2K1C hypertensive mice, this effect of
G-CSF was intensified, indicating a synergic effect of
angiotensin II on the mobilization/production of MNCs
from the spleen. This observation is supported by the
findings that angiotensin II may stimulate the proliferation
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